Cardiovascular Disease (CVD)

Impaired Renal Function Raises Risk of Advanced Coronary Atherosclerosis

Jody A. Charnow March 02, 2010

Coronary atherosclerosis severity is significantly associated with decreased renal function, according to researchers.
 

Fatigue Increases Cardiovascular Risk in ESRD Patients

Jody A. Charnow February 25, 2010

Cardiovascular events are twice as likely to occur in highly fatigued patients, recent study shows.
 

Albuminuria and Heart Disease Linked Only in White Diabetics

John Schieszer January 22, 2010

Albuminuria is strongly associated with the severity of calcified atherosclerotic plaque (CP) in white but not black individuals with type 2 diabetes, according to a new study.
 

Statin May Prevent Cardiovascular Disease in Kidney Disease Patients

Jody A. Charnow January 15, 2010

Lovastatin may prevent development of cardiovascular disease (CVD) in CKD patients, according to study findings published in the American Journal of Kidney Diseases (2009; published online ahead of print).
 

Binder Prevents CAC Progression

Jody A. Charnow January 12, 2010

SAN DIEGO—Lanthanum carbonate stops progression of coronary artery calcification (CAC) in hemodialysis (HD) patients, preliminary data from a small pilot study suggest.
 

Impaired Renal Function Raises Risk of Advanced Coronary Atherosclerosis

Jody A. Charnow January 08, 2010

Coronary atherosclerosis severity is significantly associated with decreased renal function, according to researchers.
 

Endocrine Therapy for Prostate Cancer May Hike Cardiovascular Disease Risk

Caroline Helwick December 17, 2009

Study reveals an increased risk of MI and other heart problems.
 

A New Look at High Hb Goals

Jody A. Charnow December 10, 2009

Heart failure and diabetes could make reported risks clinically undetectable.
 

Dialysis Patients Often Given Wrong Antithrombotics for PCI

Jody A. Charnow December 08, 2009

Researchers who studied a group of dialysis patients undergoing percutaneous coronary intervention (PCI) found that one fifth of them received antithrombotic medications that were contraindicated or not recommended.
 

Telmisartan Okayed for Cardiovascular Risk Reduction

Jody A. Charnow November 19, 2009

Boehringer Ingelheim Pharmaceuticals has received approval for a new indication for its angiotensin II receptor blocker Micardis (telmisartan): cardiovascular risk reduction in patients aged 55 years and older who are at high risk of experiencing major cardiovascular events and are unable to take ACE inhibitors.
 
Take a look back at our thorough coverage from Renal Week 2009 featuring daily articles in four subject areas.
Articles | Video | Photos

Job Search


From Cleveland Clinic is a regular monthly department that reports on research, events, and other activities at the Cleveland Clinic in Ohio.